EXECUTIVE CHAIRMAN & CHIEF EXECUTIVE OFFICER, ARC FERTILITY

David Adamson is a consulting reproductive endocrinologist and surgeon, Medical Director of Equal3 Fertility, Clinical Professor ACF at Stanford University, and Associate Clinical Professor at UCSF. He is Past President of the ASRM, SART, AAGL, the Committee on Reproductive Medicine for FIGO and several other major gynecological societies. He is Chair of the International Committee Monitoring ART, President of the World Endometriosis Research Foundation and ex officio Board member of the IFFS. He is a member of many prestigious professional societies and has been a board member and advisor to government, industry, professional and patient organizations. He has over 300 peer-reviewed and other scientific/medical publications and has lectured extensively nationally and internationally on assisted reproductive technologies, endometriosis, reproductive surgery and infertility. Dr. Adamson led the committee that created The FIGO Fertility Toolbox and the organization that created the global Endometriosis Phenome and Biobanking Harmonization Project (EPHect), and he created the Endometriosis Fertility Index, all electronic tools used globally to improve health care for reproductive age women.

He is Founder, Chairman and Chief Executive Officer of Advanced Reproductive Care (ARC Fertility), the largest United States network fertility company. He has been recognized as one of the best 400 physicians for women in America and received the Outstanding Achievement in Medicine award from the Santa Clara County Medical Society, a Certificate of Special Congressional Recognition for contributions to the community, Distinguished Surgeon award from the Society of Reproductive Surgeons, Honorary Life Membership from the Canadian Association of Internes and Residents, the Barbara Eck Founders Award from RESOLVE, several honorary memberships and professorships, and the ASRM Distinguished Service award for his outstanding achievements in advancing the practice of reproductive medicine. Dr. Adamson has been honored with the CEO of the Year Award by CEO Monthly.

PROGRAM DIRECTOR FOR YOUNG & HEALTHY

Since July of 2013 Liz Arnold has been with Young & Healthy, a nationally recognized program in Pasadena, CA that connects low-income uninsured children with volunteer doctors who will provide them with care at no cost. Liz is the direct supervisor of the insurance enrollment, health referrals, and outreach teams. In addition to direct program and staff oversight, Liz leads community outreach, oversees data collection and analysis, and contributes to external communications. As Program Director, Liz has been instrumental in leading Young & Healthy to develop a program, bringing the most current research and best practices around the concept of Trauma Informed Care.

Liz co-authored a research-based, Trauma Informed Care manual for use in Early Childhood Settings. As part of the resources provided with the manual, developed, and implemented a teacher training model for use with Early Childhood settings and presented this model at national conferences such as the IVAT national conference in 2022. Liz has a distinguished career in education, non-profit, and volunteer sectors with experience in senior management and executive boards. She has excellent relationship-building skills, the ability to manage multiple projects simultaneously, and fosters a cohesive team. With a strong knowledge base and excellent presentation skills, she is a skilled trainer on Trauma Informed Care, Resilience Building, and Brain Development. She holds a BS in Child Development and a MS in Psychology with emphasis on Child and Adolescent Development.

BIOTECH COMMERCIAL EXECUTIVE, INDEPENDENT CONSULTANT, and STRATEGIC ADVISOR

DAN BELTRANI is a successful commercial leader with a proven track record of surpassing revenue and profit targets in the biotech and pharmaceutical industries. He has a deep passion for leading and inspiring teams and building businesses that deliver on a mission to improve lives and better serve patients and the health care professionals who care for them. Dan has demonstrated success in a range of activities: talent management, strategic business planning, new product development, product launches, portfolio management, orphan disease, third party alliances, limited distribution networks, and national genetic screening programs.

Currently, Dan is supporting AscellaHealth, in acquisitions and mergers. AscellaHealth is a global Healthcare & Specialty Pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offering a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies.

Prior to his engagement at AscellaHealth, Dan was Vice President, Head of US BioPharma Marketing at Grifols for over 10 years. He built and led a team of HCP and consumer marketing professionals responsible for developing strategic plans and aligned tactical execution for US BioPharma rare disease business. Diverse portfolio spans allergy, immunology, neurology, pulmonology, hematology, and specialty categories. Total revenues exceeded $3B.

BRANDT VENTURES, CEO

JEFFREY BRANDT founded the award-winning Ability Prosthetics and Orthotics, an evidence-based P&O practice with fourteen offices across three states. Since its inception in 2004, Ability has led the advancement and implementation of outcome measures in daily practice, prioritizing a focus on patient care delivery, business analytics, community based adaptive programs and comparative effectiveness product research and development. Brandt also established Lifenhanced magazine and is a co-founder of Kinetic Revolutions of which the most notable product is the height-adjustable pylon for use on prosthetic limbs. Ability was acquired in 2020 by global leader, Ottobock Healthcare, where Brandt served as the VP of Clinical Operations and the Director of Business Development for Ottobock.Care until 2022.

After graduating from Penn State University, Brandt completed the prosthetics technician program at Spokane Falls Community College and then attended the Northwestern University Feinberg School of Medicine’s Prosthetic & Orthotic programs. He completed orthotic and prosthetic residencies at the Rehabilitation Institute of Chicago and Lawall P&O, servicing A.I. DuPont Children’s Hospital, respectively. As a student, Brandt was awarded the Gunther Gehl Prosthetics Scholarship by the Midwest Chapter of the American Academy of Orthotists and Prosthetists (AAOP) and has been named to the O&P News 175, is a ROMP Empowerment Through Mobility Award winner and most recently, received the AAOP’s 2022 Distinguished Practitioner Award.

Brandt has served as a board member (and past treasurer) for the American Orthotic & Prosthetic Association (AOPA), is an advisory board member of two O&P master’s programs, as well as an advisor & investor in multiple early-stage healthcare ventures. He recently published a manuscript in the Canadian Prosthetics & Orthotics Journal on the Changing Operational Perspectives in the Prosthetics & Orthotics Profession and planning a follow-on manuscript detailing his current efforts as a member of the Limb Loss & Preservation Registry’s External Collaborative Panel (ECP), focused on operationalizing the registry.

PRESIDENT and CEO for CPR STRATEGIC MARKETING AND COMMUNICATIONS

Joseph Carabello has been involved in a broad range of developmental and operational activities relating to marketing communications throughout his career spanning healthcare, managed care, hospital marketing, medical travel, e-business and technology sectors. Holding key positions in several managed care organizations, as well as venture-based startups and consulting firms, Mr. Carabello has extensive experience in the healthcare industry. He has served on the board of numerous companies including managed care organizations, physician partnerships, and public service organizations.

In addition, Mr. Carabello has acted as a consultant to the Office of Health Maintenance Organizations of the U.S. Department of Health and Human Services on marketing HMOs. He has served on the Board of Health Systems Agencies (HSAs) in New Jersey and Louisiana. A US Army Veteran, Carabello has served on several corporate and community boards, including Alvin Healthcare, Unotron LTD, Sphera Global Healthcare, The Bergen Community College Foundation, and The Molly Foundation for Juvenile Diabetes. Mr. Carabello recently initiated and funded Hannah’s Kitchen, a free food pantry for the underserved, located at a FQHC in a Northeast food desert.

CHIEF CREATIVE OFFICER for CPR STRATEGIC MARKETING AND COMMUNICATIONS and TLI Senior Fellow

Laura Carabello, founder and principal owner of CPR Strategic Marketing and Communications, has worked with over 1,000 companies, including public and private organizations, as a strategic consultant. She has been instrumental in the growth and development of multiple organizations both domestic and worldwide. She currently serves on the International Committee of the Self Insurance Institute of America and serves as special advisor to the American Macular Degeneration Foundation.

Recognized for innovation, Laura was on the founding team of Teladoc, the world’s leading telemedicine company. She has been invited by the US Federal Trade Commission to testify on healthcare advertising and marketing ethics and was recently tapped to develop special projects for Forbes magazine. She is the publisher and managing editor of Medical Travel and Digital Health News, the authoritative, online business-to business international newsletter of the medical tourism industry covering US domestic and international medical travel.

CHIEF EXECUIVE OFFICER of HEALYTICS

Peter serves as Chief Executive Officer of Healytics, a genetic data management platform and COO/EVP of CRE Technologies, leading the development of cyber solutions and products for the healthcare landscape. Pete has more than thirty-five years of experience in developing very complex technology solutions, across a wide spectrum of verticals including healthcare, media, manufacturing and cyber. He founded and led Performance Technology Group, an infrastructure engineering and outsourcing service provider focusing on the healthcare and intel markets. PTG, Inc. was sold to World Wide Technology in 2009 winning the prestigious Association of Corporate Growth’s Deal of the Year Award.

Previously, Pete was a Senior Staff member at Johns Hopkins Bloomberg School of Public Health where he supported a variety of research studies including Migraine Headache, Prospective study of Central Nervous System Function in Amateur Boxers and the Human Genome.

PRESIDENT AND CEO, W MEDICAL STRATEGY GROUP

DoHyun Cho is the founder, president and CEO of a consulting company W Medical Strategy Group based in NY and NJ.  W Medical Strategy Group is a healthcare consulting company that provides expertise and networks in the US-Asia Pacific region to help companies achieve success. Throughout 10 years of operation, WMSG has made an unparalleled track record in US/Asia cross-border collaboration, completing over 300+ projects.

 W Medical Strategy Group has 5 subsidiaries including World Asian Medical Journal (publication), New York Health Forum (conference), W MediTech (device distribution), W MedicalCare (healthcare service) and greenalley (beauty e-commerce). Before establishing W Medical Strategy Group in 2014, DoHyun was the president of Korea Health Industry Development Institute (KHIDI) USA in New York, a specialized agency of Ministry of Health of Republic of Korea. As the president of KHIDI USA, he was in charge of all the KHIDI’s activities in the United States and Latin America for 6 years. Prior to become the head of KHIDI USA, he worked for KHIDI Headquarter in Seoul, Korea as a senior researcher.

He is known as an expert in organization strategy, international affairs, global trades in healthcare and life sciences industry. He had actively involved in a lot of activities in and out of industry including serving as the advisory member for the Asia-Pacific Economic Cooperation (APEC) Harmonization Center, Korean government delegate for APEC LSIF, healthcare division representative for Korea-US Business Council, steering committee member for Korean American Chamber of Commerce. He also served as the board member for publicly traded biopharma companies of Korea, advisory board member for Trans-Pacific Health Sciences Dialogue and columnist for several South Korean News platforms. He is currently serving as the president of New York Health Forum, managing editor of World Asian Medical Journal, and advisor for multiple investment firms including DTC capital. He has received many recognizable awards including achievement award from the Ministry of Strategy and Finance of Korea, and also had been appointed as advisor for the governor of province governments of Korea.

FOUNDER, HEALTH DESIGN PLUS

Ruth Coleman has spent her career promoting healthcare quality, patient advocacy, and appropriate cost.  She founded Health Design Plus, a licensed Third Party Administrator after 20 years’ experience in the healthcare industry which included medical center and health plan executive management, nursing education, and patient care.  In addition to managing large employer health benefit plans, Health Design Plus became the national leader in domestic medical travel serving Fortune 50 companies.  Since retiring as CEO, through ValTrans Health she consults with healthcare organizations on creating value-based transformation and strategic development of direct employer relationships.

Under Coleman’s direction, Health Design Plus was named to Inc. 500, Weatherhead 100, and she was named one of the Top Ten Women Business Owners of Northeast Ohio, a Girl Scouts of Northeast Ohio Woman of Distinction, and was a finalist for the Ernst and Young Entrepreneur of the Year Award.  She serves on several Boards, including for Aequum Health, Girl Scouts of Northeast Ohio, and past President of Future Vision Foundation.  She holds a BSN from Widener University and an MA from Ohio State University.

OWNER, 2FIVE SPORTS RECRUITING

Born in St.Louis, Mo and raised in San Bernardino, Ca Mark knows  the meaning of hard work and determination.  To win a full football scholarship at Cal State University after living in those two cities and attending local schools is testament to his dedication to performance excellence. After college, he was drafted by the NY Giants in the 2nd round (44th overall) in the 1986 NFL Draft. Mark spent thirteen years as a professional football player in the positions of cornerback and safety. In his first year with the NY Giants, he started at cornerback, and the Giants won Super Bowl XXI.  Five years later, the team won Super Bowl XXV, and he was awarded Defensive MVP.  He played in Super Bowl XXXII with the Green Bay Packers, and while the team did not capture the title, Mark says it was a memorable experience. He knows the value of hard work and determination...and winning Super Bowls.

After his playing days, he wanted to help kids in his hometown and nationally and started his company 2Five Sports Recruiting. The company works with school districts helping student-athletes gain exposure for sports scholarships. As an active player, he served as a consultant the National Football League Players Association (NFLPA), the union for professional football players in the National Football League. Today, he serves as a consultant to the NFL Alumni Association, the oldest, most well-known and well-respected retired player organization in professional sports. He lives with his children in Overland Park, KS.

FOUNDER and CEO at GENEGINI

Dr. Day joins TLI from the United Kingdom, expanding the Foundation’s global presence. His interests lie primarily in quantitative measurement, and he is driven to improve the quality of big, deep medical data by bringing engineering to the molecular sciences. His expertise in in nucleic acid measurement tools for quantitative integrative analyses of bio analytes, pathway function and mechanism analyses, microbiome and chronic inflammatory diseases, miniaturization for single cell studies and role of biological heterogeneity, systems biology and synthetic biology applications.

Dr. Day is the Principal Investigator in Synthetic Biology & Quantitative Genomics, Faculty of Biology, Medicine and Health Sciences, University of Manchester and Manchester Institute of Biotechnology (2007 to Present); Honorary Professor, Department of Medicine, University of Cape Town, South Africa (2021 to present); Honorary Professor, Bioengineering, Electrical Engineering & Computer Science, and Biophysics, UC Berkeley (2019 to present) and was Honorary Professor, Department of Biomedical Engineering, UC Irvine (2013 to 2018).

ASSISTANT PROFESSOR, DEPARTMENT OF DERMATOLOGY at the UNIVERSITY OF MINNESOTA

Dr. Marna E. Ericson currently serves as Assistant Professor, Department of Dermatology at the University of Minnesota. Dr. Ericson joined the University of Minnesota Department of Dermatology in 1996 as part of the Clinical Research Division team. She is Director of the research laboratory in Dermatology located in Diehl Hall and leads the Basic Science Friday resident lecture series.

Over the past 15 years, Dr. Ericson has adapted advanced imaging methodologies with new molecular techniques to improve understanding of vector-borne diseases with a long-term goal of deciphering the mechanisms and complex nature of co-infections. Her interests lie in imaging with special emphasis on single- and multi-photon laser scanning confocal microscopy. Her expertise in imaging has led to fruitful collaborations with other investigators outside the Department of Dermatology in the fields of infectious diseases, oncology, neuroscience, rheumatology, engineering, dentistry, and orthopedics.

Dr. Ericson has successfully administered collaborative projects with peer-reviewed publications as well as funding. With Innovation as a hallmark of her research endeavors, Professor Ericson has contributions like understanding and treating Cancer pain, identifying molecular targets of phytochemicals, comprehending the role of the peripheral nervous system in skin and hair biology, and recognizing the implications of Bartonellosis.

Dr. Ericson’s current research activities include cancer pain in a murine model, mechanisms of hair growth, tumor/T-cell interactions, mechanism of mammalian/tick infection, and second harmonic imaging of collagen.

Dr. Ericson became a Fellow of the Thought Leadership & Innovation Foundation (TLI) in 2018. She has contributed to Science with 47 peer-reviewed papers and has received several honors and awards in Imaging Science, including in 2013 as a Finalist in Posters/Graphics for the National Science Foundation (NSF) Science Engineering Visualization Challenge.

CHAIRMAN OF ACTIVATOR METHODS INTERNATIONAL®

Dr Fuhr is co-founder and chairman of Activator Methods International®, is the co-inventor of the Activator® Adjusting Instrument and the Activator Method Chiropractic Technique®. Established nearly 50 years ago, the Activator Method® is the world’s most widely used instrument adjusting chiropractic technique and is currently in use by 70 percent of all chiropractors. Endorsed throughout the chiropractic field, the Activator Method® is taught in nearly every college in the United States and abroad, as well as in professional seminars throughout the year.

Dr Fuhr is part of an esteemed group of healthcare and business professionals noted for their outstanding contributions to the international advancement of chiropractic.

Educating chiropractors across the world on the benefits of low-force chiropractic adjustments, Dr Fuhr continues to speak and teach worldwide with events in Japan, Australia, England, Spain and Ireland as well as overseeing a full slate of AMI training seminars in the U.S. and Canada.

He is credited with more than 25 peer-reviewed publications, 13 domestic patents, 47 worldwide trademarks and more than 100 copyrighted works. In 2008, Dr Fuhr published the second edition of the technique textbook, The Activator Method, globally acknowledged as the standard reference for instrument adjusting. A native of Minnesota, Dr Fuhr received his chiropractic training at Logan University. He is married to Judi Fuhr and resides in Phoenix, Arizona, which is also home to the world corporate headquarters of Activator Methods International ®.

CEO and FOUNDER SHIFA PRECISION, FACULTY HARVARD MEDICAL SCHOOL, and U.S. CONGRESSIONAL SCIENCE ADVISOR

Dr. Neena Haider, renowned geneticist and visionary scientist, is the founder of Shifa Precision and a faculty member at Harvard Medical School. A pioneer in gene therapy, Dr. Haider has brought multiple life-changing therapies to the clinic. Dr. Haider was a key contributor to the Human Genome Project and during her career has identified more than a dozen genes linked to various diseases, including blindness, kidney disorders, and autism.

With a strong commitment to scientific leadership, Dr. Haider has served and serves in numerous leadership roles at institutions such as Harvard Medical School, National Institute of Health (NIH), the U.S. Congress, National Science Foundation (NSF) and NASA. Dr. Haider's groundbreaking research has been published in leading scientific journals, cited over 3000 times, and incorporated into global textbooks.  Dr. Haider’s gene therapy lab at Harvard discovered novel types of gene therapies that have broad capabilities to treat multiple forms of blindness. She has a U.S. patent issued and her therapies were granted several orphan disease designations (ODD), Regenerative Medicine Advanced Therapy (RMAT) and expanded access status with the FDA  that allows expeditious development and review of promising therapies, as well as European Medicines Agency (EMA) approval for clinical trials.

Recognizing the need for personalized healthcare, Dr. Haider is developing Shifa Precision, a comprehensive, whole-health, AI-driven, diagnostic test solution. The innovative approach empowers physicians to proactively mitigate diseases through predictive and preventative measures. Shifa Precision will provide accurate and valuable tests while significantly reducing the time and costs associated with fragmented, misdiagnosed, and mistreated care, ultimately improving patient outcomes.

Physician, CEO of Progenabiome and Ventura Clinical Trials, Co-founder of Topelia Therapeutics; Expert on the Gut Flora (Microbiome) and cutting-edge medical research;
Writer, Editor, World-Renowned Speaker, Published Author of “Let’s Talk Sh!t” , Regenesis 

MD: University of Miami, Residency: Jackson Memorial Hospital, Fellowship: University of Florida 

As the first woman  accepted into the University of Florida as a Clinical Gastroenterology Fellow, Dr. Sabine Hazan is a pioneer in the medical field. She has published articles in numerous prestigious medical journals, and is the Series Editor on the microbiome for Practical Gastroenterology , a peer review journal that reaches 18,000 gastroenterologists. She is also a speaker for the World Congress of Digestive Disease, MAGI, Microbiome Congress, ILADS, TACA, International Drug Discovery Science and Technology Conference and NIST (National Institute of Standards and Technology). As a specialist in gastroenterology, internal medicine, and hepatology, Dr. Hazan has used her medical expertise in many regards over the last two decades.

Dr. Hazan is  the CEO of Ventura Clinical Trials, where she has 20+ years experience leading clinical trials for cutting-edge research on various medical issues and has done over 300 clinical trials for pharmaceutical companies.  Since March 2020, she has been at the forefront of COVID-19 research, leading ongoing FDA-approved clinical trials for treatment and prophylaxis ON Hydroxychloroquine, Zpack, VIT C D , Zinc And  IVM

She is also the  founder & CEO of Progenabiome, a genetic sequencing research laboratory, she leads 35+ studies investigating the role of the gut flora in various diseases  

Through their study exploring the role of the gut flora in COVID-19, Progenabiome became the first lab worldwide to detect SARS-CoV-2 from Patient Fecal Samples by Whole Genome Sequencing and the lab that showed a susceptibility marker for COVID in the microbiome. 

Dr Hazan is mastering Familial fecal transplant showing hope for kids with Autism. She created The Malibu Microbiome meeting where physicians who perform fecal transplant can discuss their findings freely.

CHAIRWOMAN AND CHIEF EXECUTIVE OFFICER, HD NURSING

Amy has 25 years of nursing experience including over a decade of med/surge and neuro nursing followed by unit management and hospital administration. In 2015, she earned a Doctor of Philosophy in Nursing Science and has since published and spoken extensively on the subject of falls and injury prediction and prevention. She retired from UAMS in 2018 after 26 years of service to dedicate her time fully to HD Nursing. She is adjunct faculty at UAMS College of Nursing. In 2023  she was inducted as a Fellow of the American Academy of Nursing (Academy), a significant milestone in a nurse leader’s career in which their accomplishments are honored by their colleagues within and outside the profession. As an entrepreneur, she mentors others to help them with their own endeavors. Amy also serves as the Chair of the HD Nursing Board of Directors.

FOUNDER of disABLED LIFE ALLIANCE

Paul Kent is the Founder of disAbled Life Alliance, a public benefit corporation dedicated to bringing about meaningful change within the disabled community. He embarked on this mission on December 1st, 2020, by undergoing a groundbreaking bilateral below-the-knee amputation procedure known as the Ewing Amputation. In becoming the first bilateral "non-traumatic" patient to participate in Dr. Matthew Carty's clinical surgical study at Brigham and Women's Hospital, Paul successfully put an end to a decade-long, life-threatening health crisis.

Before his involvement in disability advocacy, Paul spent a significant portion of his professional career in the financial services industry. He held various senior positions at Jefferies and Company, ultimately overseeing US Equity Sales and Trading. Following his retirement from Jefferies, Paul provided guidance to smaller investment banks on various matters and launched Idlewood Capital Partners, a firm dedicated to supporting first-time fund managers. During this time, he cultivated relationships with

ultra-high-net-worth individuals and family offices, which ultimately led him to become involved in the social impact movement. In 2018, Paul merged his capital markets business with a philanthropic advisory firm. Through this collaboration, he developed a new business model that not only advised family offices and foundations on gifting, granting, and impact investment activities but also formulated and executed a comprehensive plan to achieve the desired social impact.

Drawing from both his professional expertise and personal experiences, Paul has created an innovative model that will focus exclusively on addressing the challenges faced by the disabled community.

Paul is relishing the opportunities that his renewed lease on life has presented to him. He considers his Ewing Amputation to be a precious "gift" that has enabled him to pursue an active, healthy, and adventurous lifestyle that eluded him for over a decade. After the ten-year hiatus and post-amputation, he has resumed many of these pursuits, including running the past two Boston Marathons, where he raised a substantial amount of funds for the Stepping Strong Center for Trauma Innovation and the Spaulding Rehabilitation Hospital President's Fund.

Paul is the proud father of two sons, Robert and Peter, who are the inspiration behind his quest to Facilitate Meaningful Change! His oldest son Robert, a USN Officer resides in Bremerton Washington. Paul’s younger son Peter is a thriving technology entrepreneur living and working in New York.

CHIEF EXECUTIVE OFFICER OF MINES AND ASSOCIATES

Dr. Daniél (Dani) Kimlinger is the Chief Executive Officer of MINES and Associates. Dani has a background in human resources and organizational psychology and leadership. Beyond her professional endeavors, Dani actively contributes to the community by volunteering and serving on various non-profit and professional boards. Her dedication and contributions have been acknowledged through numerous acknowledgements and awards.

Dani’s academic background includes an undergraduate degree in Psychology and Sociology, and she holds a Master of Health Administration (MHA). She furthered her education by completing a Ph.D. in Organizational Leadership from The Chicago School of Professional Psychology, specializing in Business Psychology. To enhance her leadership skills, Dani also earned a certificate in Executive Leadership from Cornell University. With a passion for people, she finds joy in various activities such as reading, running, weightlifting, and outdoor pursuits like backpacking, hiking, snowboarding, trail running, and camping.

EXECUTIVE DIRECTOR, EPIDEMIC ANSWERS

BETH LAMBERT is a former healthcare consultant and teacher. As a consultant, she worked with pharmaceutical, medical device, diagnostic and other health care companies to evaluate industry trends. She is the author of A Compromised Generation: The Epidemic of Chronic Illness in America’s Children (Sentient Publications, 2010). She is also a co-author of Epidemic Answers’ Brain Under Attack: A Resource for Parents and Caregivers of Children with PANS, PANDAS, and Autoimmune Encephalitis. In 2009, Beth founded Epidemic Answers and currently serves as Executive Director. Beth attended Oxford University and graduated from Williams College and holds a Masters Degree in American Studies from Fairfield University. She is a member of Alpha Sigma Nu, the Jesuit Honor Society. Beth is also the mother of three young children.

DIRECTOR OF GRANTS, PARTNERSHIPS, ADVOCACY for the AMERICAN MACULAR DEGENERATION FOUNDATION

Matthew Levine has been a communications professional for 30 years, with a vision research focus since 2003. At the American Macular Degeneration Foundation (AMDF), his portfolio includes the expansion of the AMDF grant program, the development of strategic partnerships, advocacy engagement, and the creation of educational content. He also is a painter, concentrating in watercolor. He graduated from Oberlin College with a dual major in Creative Writing and English, and received a Master of Fine Arts degree (in Creative Writing) from Columbia University.

SENIOR ASSOCIATE/PRINCIPAL AEA & PROJECT DIRECTOR

In more than fifty years in education, John McGuire has served urban, suburban and rural school districts in the roles of special education teacher, director of special programs, chief operations officer, director of instruction, assistant superintendent and superintendent of schools.  Mr. McGuire’s role-related areas of responsibility have included extensive experience in program development and implementation, supervision and mentoring of staff in diverse professional disciplines and program accountability.  He has served as a faculty member with the New York State Superintendent Development Program, and as an assistant professor with the State University of New York’s graduate program in Educational Leadership and Administration at Oswego.  Mr. McGuire is a life member of the New York State Council of School Superintendents.

FOUNDER AND EXECUTIVE DIRECTOR of the TRANSLATIONAL MEDICINE GROUP

Dr. B. Robert Mozayeni is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently.

Dr. Mozayeni is a Rheumatologist with graduate and post-graduate physician-scientist training from Albany Medical College, Yale University, Howard Hughes Medical Institute, and the National Institutes of Health (NCI, NHLBI, and NIAMS). He is presently in private practice in Bethesda, MD where he specializes in chronic inflammatory diseases having rheumatic and neurovascular manifestations.

Dr. Mozayeni is the founder and Executive Director of the Translational Medicine Group where he has developed and commercialized software that supports data-driven methods to accelerate the evaluation and improvement of patient-centered care pathways. Under an ongoing research collaboration, Dr. Mozayeni maintains an observational clinical evaluation of the significance of Bartonella infection in a cohort of several hundred human patients with otherwise unexplained chronic conditions. Clinical correlations between Bartonella species and various conditions are being determined as part of ongoing research which continues to redefine diagnostic and therapeutic options as dictated by clinical experience.

FOUNDER AND MANAGING PARTNER OF SPRINGHOOD VENTURES

Springhood Ventures is an early-stage venture capital firm that invests in life science and healthcare companies transforming the health and care of children. Mr. Parker founded Springhood following his success creating and managing CH Innovations, the impact-first venture capital subsidiary of the Charles H. Hood Foundation, a Boston-based family foundation that supports pediatric research, where he also serves as a trustee.

John is currently a director or observer on the boards of Xploro, Inc, Plakous Therapeutics, Deck Therapeutics, SmolTap, Argus Cognitive, Anida Pharma, Mesentech, Inc., and Prapela, Inc.. He also serves on the advisory boards of multiple nonprofit entities, largely around mission-driven healthcare investing. He is a frequent speaker on pediatric innovation and mission investing.

Previously, John spent 25 years in the alternative investment industry, including senior roles in venture capital, private equity, and hedge funds. Early in his career he worked in international merchant banking. Although currently living in the Boston area, John spent portions of his career in New York, Tokyo, and Sydney and has done business in over 20 countries on 6 continents. John has a BA from Dartmouth College and an MBA from Dartmouth’s Tuck School of Business.cription

BOARD OF DIRECTORS FOR THE FEDERAL HOME LOAN BANK (FHLB) AND BOARD OF DIRECTORS FOR THE TASK FORCE FOR GLOBAL HEALTH

Edwina Payne is a board member and former global CIO with over thirty years of leadership experience gained from growing, scaling and transforming global businesses in the Life Sciences and CPG industry with revenues ranging from $1B-$200B. She leverages her experiences in technology strategy development, digital transformations, supply chain strategy, manufacturing, acquisitions, divestitures, and cybersecurity to identify opportunities for growth and efficiency as well as enhanced governance and oversight in both public and private companies. She has lived internationally and is fluent in Spanish and Portuguese. Edwina enjoys adding value as a member of corporate boards, its committees, and working groups.

Edwina has served on the Board of Directors for the Federal Home Loan Bank (FHLB) of Atlanta since January 2020. She is Vice-Chair of the Enterprise Risk and Operations committee, and sits on the Audit, Governance and Compensation committees. During her tenure she has served on several search committees for board directors, navigated a CEO transition, as well as enhanced the risk oversight and governance functions. She also serves on the Board of Directors for the Task Force for Global Health, sitting on their Finance and Governance committees. Since joining the board in 2023 Edwina has strengthened the board member evaluation and recruitment process.

Edwina’s board service draws on her extensive career experience in multiple Fortune 200 companies as well as smaller PE-backed firms that have complex global systems and structures, with sales, manufacturing and supply chain across multiple regions and locations in highly regulated industries. She is able to leverage this experience to provide insight into how digital and legacy technologies impact M&A, business transformation, growth and cyber risk as well as impacts to work force talent and culture. She has held senior leadership roles at Kellogg Company, Johnson & Johnson, Zimmer Biomet, Avanos Medical, McKesson and Varsity Brands, on assignments in the United States, Brazil and Mexico.

Edwina earned her bachelor's degree in computer technology from Purdue University in 1986. She was named a Distinguished Alumni by Purdue University in 2009. In 2012, she received the CIO 100 award from IDG. Edwina was also a finalist for the Georgia CIO of the Year in 2018 and 2022, and she was recognized by HMG as a 2019 Top Technology Executive to Watch. She is actively involved in professional director associations such as Women Corporate Directors, Extraordinary Women on Boards, and Private Directors Association.

VICE PRESIDENT FOR CENTERS OF EXCELLENCE AT CONTIGO HEALTH

Heather Ridenoure is a Vice President for Centers of Excellence at Contigo Health. She is responsible for managing all aspects of the Centers of Excellence P&L including product, operations, product, quality, data/reporting, sales, marketing, and client management. Heather is also a Disease Specific Care Reviewer for The Joint Commission. Heather has 24 years of experience in various aspects of healthcare including product design, quality/regulatory, project management, program operations, process improvement, benefit design, provision of clinical care, revenue cycle, and electronic medical record. She has worked with large self-funded employers and providers to create direct relationships and ultimately create solutions to solve some of healthcare’s most complex problems. Heather brings a balanced perspective to the complicated health care environment with her clinical, operational, and administrative experience. Heather lives in Rogers, AR with her husband and three children.

CHIEF EXECUTIVE OFFICER of ACQUIRED IMMUNE MEDICINES, INC

Dr. Robin Robinson serves concurrently as a Fellow for Regenerative Medicine and Chronic Diseases at TLI, the acting Chief Executive Officer of Acquired Immune Medicines, Inc. developing new vaccines for influenza and other emerging pathogens, and an independent senior executive consultant for many pharmaceutical and biotechnology companies in the U.S. and Europe. He leads TLI’s development of cellular therapies to treat wounds from thermal, radiation, and diabetic wounds to establish a new regenerative medicine program.

He reentered the private pharmaceutical industry sector after retiring in 2016 from federal public service at the U.S. Department of Health and Human Services, where he served from 2008 - 2016 as the first director of the Biomedical Advanced Research and Development Authority (BARDA) and Deputy Assistant Secretary for Preparedness and Response. Dr. Robinson brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of drugs, vaccines, diagnostics, and medical devices for man-made threats, pandemic influenza, and emerging infectious diseases. 38 of these medical countermeasure products supported by BARDA supported under his leadership were FDA approved. Under his leadership, BARDA established premier programs that developed treatments for acute radiation syndromes (ARS) with industry partners; novel cellular therapy technologies were utilized to treat ARS-associated neutropenia and thermal and radiation burns. In 2018, Dr. Robinson was recognized as one of top 100 innovators in medicine.

While at BARDA, Dr. Robinson served from 2004-2008 as the Director for the Influenza & Emerging Disease Division. Dr. Robinson established a program with scientific and technical experts to implement the national and global strategic plans and policies for the development of new influenza antiviral drugs, vaccines, and diagnostics outlined in the National Strategy for Pandemic Influenza. For his leadership in this role, Dr. Robinson was the recipient of the Department of Defense’s Clay Dalrymple Award in 2008, the HHS Distinguished Service Award three times, and a finalist for the Service to America Medal in 2009. From 2013- 2015, Dr. Robinson was recognized as one of the top 50 most influential persons worldwide in vaccines by Vaccine Nation.

Prior to public service, Dr. Robinson served as the Director of Vaccines at Novavax, Inc. (Rockville, MD) from 1995-2004, where he led the development of 20+ vaccines to hepatitis B and E, influenza, noroviruses, and human papilloma viruses from early development, clinical trials, manufacturing scale-up, and commercialization through FDA licensure. He developed patented platform vaccine technologies including virus-like particles and subunit protein vaccines for human pathogens including malaria, human papilloma, hepatitis, and influenza and for prostate, melanoma, and cervical cancers. Dr. Robinson pursued research from 1983-1992 on the molecular pathogenesis of herpesviruses and HIV while on faculty in the Department of Microbiology and Immunology at the University of Texas Southwestern Medical School.

Dr. Robinson received a Bachelor of Science degree from Millsaps College and a doctoral degree from the University of Mississippi Medical School in microbiology. He completed a NIH postdoctoral fellowship with the State University of New York at Stony Brook in molecular oncology.

Dr. Robinson also serves on the Senior Advisory Group for the World Health Organization (WHO) on emerging infectious diseases and pandemic influenza. Additionally, he continues to serve as an editorial board member and reviewer for several professional scientific and technical journals on virology, vaccines, public health, and biotechnology.

FOUNDER, MOTIVE LABS

Mark Roser is a founder of Motive Labs, a small business that focuses on new product development with core disciplines in lower limb gait rehabilitation as well as vision loss prevention. 

Mark has been Principal Investigator on research funded by the National Institutes of Health (NIH), Defense Health Agency (DHA), National Science Foundation (NSF), National Institute for Disability, Independent Living and Rehabilitation Research (NIDILRR), and major biopharmaceutical companies. He is now on adjunct faculty of the University of Nebraska at Omaha, Department of Biomechanics and is a volunteer researcher with the Veterans Administration.

He serves on multiple volunteer committees, including NIH Center for Scientific Review panels, the US Special Operations Forces innovation group (SOFWERX), BirdAbility (A national group expanding trail accessibility in public lands for people with mobility issues), the Wearable Robotics Association, and several local organizations.

As a graduate of the University of Pennsylvania’s School of Engineering, Mark started his career in Research & Development in Sweden, working with ITT in developing computer models for hydro-turbine design.  He has also held R&D and Marketing management positions with Pitney Bowes. 

Motive Labs’ lower limb exoskeleton research program (FlyBand®) boosts mobility, increases walking capacity, and reduces load on the soft tissues.  Our research in exoskeletons spans multiple categories, including prevention of diabetic foot ulcers and amputation (collaborations with USC, Rancho Los Amigos National Rehabilitation Center and University of Arizona), frailty and fall-risk prevention (collaboration with Baylor College of Medicine), return to activity after injury (University of Nebraska at Omaha), reducing gait asymmetry and pain in people with limb loss (University of Nebraska at Omaha), and multiple others.

Motive Labs’ vision loss prevention program (KeepSight®) helps people to recognize the signs of vision loss (macular degeneration & diabetic retinopathy) early, so that treatment can be started early.  Research has been conducted with Wilmer Eye Institute/Johns Hopkins funded by the National Eye Institute, and Moorfields Eye Hospital, UK funded by the UK National Health Research Service.

Motive Labs also provides consulting services to leading scientific & engineering organizations to develop and support early-stage innovation processes.  Clients include Pfizer (strategic planning, scenario planning, IP management, voice of the customer in Alzheimer’s disease, head trauma, & cardiovascular surgery), Genentech (Ophthalmology), Eaton Corporation (commercial vehicle drivetrains, electronic switchgear), Cummins (high efficiency diesel powertrains), Kenworth (electrified truck powertrains), Printpack (scenario planning and voice of the customer), CVS Health (Customer experience), Warner Lambert (Upper respiratory),  and many others.  Mark lives in eastern Connecticut.

ROSSIGNOL MEDICAL CENTER

Dr. Rossignol, MD FAAFP is a board-certified family physician. He received his Doctorate of Medicine at the Medical College of Virginia and completed his residency in family medicine at the University of Virginia. Coming from an academic background, Dr. Rossignol searched the medical literature looking for a solution after both of his children were diagnosed with autism. He has made it his mission to research and publish in autism. Since 2006, he has 55 papers, abstracts, editorials, and book chapters (including those in press) concerning autism and related conditions. Dr. Rossignol has a special interest in autism spectrum disorders, PANS/PANDAS, cerebral palsy, and related neurological and developmental disorders as well as medically complex children and adults. Dr. Rossignol is a Fellow of the American Academy of Family Physicians (FAAFP) and a Fellow of the Medical Academy of Pediatric Special Needs (FMAPS). Dr. Rossignol sees patients in all three offices in California and Florida.

LEAN SIX SIGMA GREEN BELT | ACHE

Kay Van Der Vaart is a seasoned healthcare executive with a diverse background in business, innovation, strategic planning, population health, and data analytics. 

She holds an MBA with a focus on healthcare management and certification in LEAN Six Sigma methodologies, bringing a unique blend of strategic acumen and operational expertise as a health advisor. With a passion for driving organizational excellence and improving patient outcomes, Kay has led initiatives to streamline processes, optimize resources, and enhance the overall efficiency of healthcare delivery systems. Her leadership style is characterized by a collaborative approach, fostering cross-functional teamwork and a culture of continuous improvement. In addition to Kay’s business acumen, she is an experienced marketing and public relations professional, hosting live and recorded radio programs, webinars, and presenting healthcare topics on the national scene.

FOUNDER AND CHIEF MEDICAL OFFICER for MEDIORBIS

Dr. Jonathan Wiesen is a pulmonary and critical care physician, teacher, researcher and medical technology pioneer with a passion for clinical medicine and telehealth innovation.

Graduating from the Albert Einstein College of Medicine with distinction in research, he completed his training in internal medicine as well as pulmonary and critical care at the Cleveland Clinic - earning an advanced teaching degree and several teaching and research awards.

As founder and chief medical officer of MediOrbis, he leads the development of ground-breaking clinical programs for monitoring and managing chronic medical conditions and providing integrated medical specialty services. He has also developed a global network of top physicians to deliver the company’s telemedicine services worldwide.

Currently, Dr. Wiesen is a pulmonary specialist at Ben Gurion University’s Soroka Medical Center, where he directs the Cardio-Pulmonary Exercise Program. He plays an active role as an advisor to a number of medical technology companies, and serves on the board of several companies including the most active venture capital firm in Israel, specializing in clinical assessment and due diligence.

Mr. Dea Belazi leads AscellaHealth, which provides pharmacy benefit manager services to nearly 3 million people in the commercial, Medicaid and Medicare markets.

He operates the independent consultancy, AlchemiPharma, whose clients include pharmaceutical manufacturers and health plans. The consultancy focuses on many areas including pharmacy benefit strategies, formulary management, contracting, business development strategies, and health economics and outcomes research. Belazi is also the principal and owner of CrowdHealth, a social networking site for consumers to share healthcare experiences. Belazi founded and leads the business development of two other Pharmacy Benefit Managers, PerformRx and FutureScripts, which was acquired in September 2010 by Catamaran. Mr. Belazi holds a Masters of Public Health at Johns Hopkins University.

Dr. Charles Bruce Green was the 20th Air Force Surgeon General and the functional manager of the U.S. Air Force Medical Service.

He is an expert in anything related to the Military Health System, veterans’ health, medical disaster response, air evacuation, patient centered medical home, connected health, and health analytics. Dr. Green is a managing director with Deloitte Consulting LLP, serving as chief medical officer for Deloitte’s Federal Health practice.

Dr. Green is an advisor to Deloitte’s federal and commercial health clients and a thought leader in clinical public health leadership and preparedness. He serves as a consultant to health industry and corporate boards, improving private sector and government care by strategically planning sustainable models of care. He has a MD and a MPH from the Harvard School of Public Health and is board certified in Aerospace Medicine.